Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Hepatitis

  Free Subscription


Articles published in Eur J Gastroenterol Hepatol

Retrieve available abstracts of 114 articles:
HTML format
Text format



Single Articles


    February 2019
  1. SUAREZ E, Buti M, Rodriguez M, Prieto M, et al
    Hepatitis B surface antigen loss after discontinuing nucleos(t)ide analogue for treatment of chronic hepatitis B patients is persistent in White patients.
    Eur J Gastroenterol Hepatol. 2019;31:267-271.
    PubMed     Text format     Abstract available


  2. HU Z, Ni P, Fan X, Men R, et al
    Past hepatitis B virus infection was not associated with poorer response or the UK-PBC risk score in ursodeoxycholic acid-treated patients with primary biliary cirrhosis.
    Eur J Gastroenterol Hepatol. 2019;31:277.
    PubMed     Text format    


  3. MARCELLIN F, Protopopescu C, Wittkop L, Salmon-Ceron D, et al
    No influence of cannabis use on liver stiffness in HIV-HCV co-infected patients (ANRS CO13 HEPAVIH cohort study).
    Eur J Gastroenterol Hepatol. 2019;31:274-276.
    PubMed     Text format    


    December 2018
  4. WU ZX, Chen FS, Zhou XL, Huang Q, et al
    Tenofovir and telbivudine combination therapy rapidly decreases viral loads in immune-tolerant chronic hepatitis B patients awaiting assisted reproduction: an open-label, randomized, controlled study.
    Eur J Gastroenterol Hepatol. 2018 Dec 31. doi: 10.1097/MEG.0000000000001345.
    PubMed     Text format     Abstract available


  5. HU J, Zhang X, Gu J, Yang M, et al
    Serum alkaline phosphatase levels as a simple and useful test in screening for significant fibrosis in treatment-naive patients with hepatitis B e-antigen negative chronic hepatitis B.
    Eur J Gastroenterol Hepatol. 2018 Dec 12. doi: 10.1097/MEG.0000000000001336.
    PubMed     Text format     Abstract available


  6. PONZETTO A, Ciancio A, Figura N
    Delta hepatitis in resolved hepatitis B.
    Eur J Gastroenterol Hepatol. 2018;30:1528.
    PubMed     Text format    


    November 2018
  7. LYBECK C, Brenndorfer ED, Sallberg M, Montgomery SM, et al
    Long-term follow-up after cure from chronic hepatitis C virus infection shows occult hepatitis and a risk of hepatocellular carcinoma in noncirrhotic patients.
    Eur J Gastroenterol Hepatol. 2018 Nov 19. doi: 10.1097/MEG.0000000000001316.
    PubMed     Text format     Abstract available


  8. DEMERDASH HM, Elyamany AS, Arida E
    Impact of direct-acting antivirals on leukocytic DNA telomere length in hepatitis C virus-related hepatic cirrhosis.
    Eur J Gastroenterol Hepatol. 2018 Nov 15. doi: 10.1097/MEG.0000000000001306.
    PubMed     Text format     Abstract available


  9. SHAH SM, Baniya JB, Gupta BP, Shrestha A, et al
    Association between liver fibrosis and hepatitis E seroprevalence among HIV-positive individuals in Nepal.
    Eur J Gastroenterol Hepatol. 2018 Nov 5. doi: 10.1097/MEG.0000000000001308.
    PubMed     Text format     Abstract available


  10. OZARAS R, Uraz S, Demirel A, Mete B, et al
    Resolved hepatitis B virus infection: an unresolved issue of terminology.
    Eur J Gastroenterol Hepatol. 2018;30:1389.
    PubMed     Text format    


    October 2018
  11. SHAHID M, Idrees M, Butt AM, Raza SM, et al
    Hepatitis C and G virus coinfection in Punjab, Pakistan: incidence and its correlation analysis with clinical data.
    Eur J Gastroenterol Hepatol. 2018 Oct 31. doi: 10.1097/MEG.0000000000001302.
    PubMed     Text format     Abstract available


  12. LV DD, Wang ML, Chen EQ, Wu DB, et al
    A retrospective study of the efficacy of sofosbuvir plus NS5A inhibitors for patients with hepatitis C virus genotype-2 chronic infection.
    Eur J Gastroenterol Hepatol. 2018 Oct 31. doi: 10.1097/MEG.0000000000001299.
    PubMed     Text format     Abstract available


  13. DRIEDGER M, Galanakis C, Doyle MA, Cooper CL, et al
    Direct-acting antiviral hepatitis C virus treatment perturbation of the metabolic milieu.
    Eur J Gastroenterol Hepatol. 2018 Oct 30. doi: 10.1097/MEG.0000000000001292.
    PubMed     Text format     Abstract available


  14. SHAH T, Hussain W, Ali N, Sardar S, et al
    Frequency distribution and risk factors of hepatitis B virus and hepatitis C virus infections among thalassemia patients: a regional study.
    Eur J Gastroenterol Hepatol. 2018 Oct 24. doi: 10.1097/MEG.0000000000001287.
    PubMed     Text format     Abstract available


  15. KRUGER K, Krauth C, Rossol S, Mauss S, et al
    Outcomes and costs of treating hepatitis C patients with second-generation direct-acting antivirals: results from the German Hepatitis C-registry.
    Eur J Gastroenterol Hepatol. 2018 Oct 15. doi: 10.1097/MEG.0000000000001283.
    PubMed     Text format     Abstract available


  16. IBRAHIM EH, Marzouk SA, Zeid AE, Lashen SA, et al
    Role of the von Willebrand factor and the VITRO score as predictors for variceal bleeding in patients with hepatitis C-related cirrhosis.
    Eur J Gastroenterol Hepatol. 2018 Oct 2. doi: 10.1097/MEG.0000000000001272.
    PubMed     Text format     Abstract available


  17. LI B, Zhang L, Zhang Z, Yan G, et al
    A noninvasive indicator for the diagnosis of early hepatitis B virus-related liver fibrosis.
    Eur J Gastroenterol Hepatol. 2018 Oct 1. doi: 10.1097/MEG.0000000000001281.
    PubMed     Text format     Abstract available


    September 2018
  18. ESSA M, Sabry A, Abdelsameea E, Tharwa ES, et al
    Impact of new direct-acting antiviral drugs on hepatitis C virus-related decompensated liver cirrhosis.
    Eur J Gastroenterol Hepatol. 2018 Sep 21. doi: 10.1097/MEG.0000000000001250.
    PubMed     Text format     Abstract available


  19. ATTIA D, Deterding K, Cornberg J, Gebel MJ, et al
    Different kinetics of liver stiffness using shear wave elastography in patients with chronic hepatitis C infection treated with interferon-free regimens.
    Eur J Gastroenterol Hepatol. 2018 Sep 19. doi: 10.1097/MEG.0000000000001259.
    PubMed     Text format     Abstract available


  20. ABDELAZIZ AO, Nabil MM, Abdelmaksoud AH, Shousha HI, et al
    Tumor behavior of hepatocellular carcinoma after hepatitis C treatment by direct-acting antivirals: comparative analysis with non-direct-acting antivirals-treated patients.
    Eur J Gastroenterol Hepatol. 2018 Sep 7. doi: 10.1097/MEG.0000000000001264.
    PubMed     Text format     Abstract available


  21. STOURNARAS E, Neokosmidis G, Stogiannou D, Protopapas A, et al
    Effects of antiviral treatment on the risk of hepatocellular cancer in patients with chronic viral hepatitis.
    Eur J Gastroenterol Hepatol. 2018 Sep 1. doi: 10.1097/MEG.0000000000001254.
    PubMed     Text format     Abstract available


  22. FUKUI A, Kawabe N, Hashimoto S, Kamei H, et al
    Skeletal muscle mass depletion in patients with hepatitis C virus infection.
    Eur J Gastroenterol Hepatol. 2018 Sep 1. doi: 10.1097/MEG.0000000000001255.
    PubMed     Text format     Abstract available


    August 2018
  23. MUN EJ, Green P, Berry K, Ioannou GN, et al
    No difference between direct-acting antivirals for hepatitis C in hepatocellular carcinoma risk.
    Eur J Gastroenterol Hepatol. 2018 Aug 23. doi: 10.1097/MEG.0000000000001242.
    PubMed     Text format     Abstract available


  24. PASSERINI M, Schiavini M, Magni CF, Landonio S, et al
    Are direct-acting antivirals safe and effective in hepatitis C virus-cryoglobulinemia? virological, immunological, and clinical data from a real-life experience.
    Eur J Gastroenterol Hepatol. 2018 Aug 22. doi: 10.1097/MEG.0000000000001239.
    PubMed     Text format     Abstract available


  25. EL-NAHAAS SM, Fouad R, Elsharkawy A, Khairy M, et al
    High sustained virologic response rate using generic directly acting antivirals in the treatment of chronic hepatitis C virus Egyptian patients: single-center experience.
    Eur J Gastroenterol Hepatol. 2018 Aug 9. doi: 10.1097/MEG.0000000000001228.
    PubMed     Text format     Abstract available


  26. GAYAM V, Tiongson B, Khalid M, Mandal AK, et al
    Sofosbuvir based regimens in the treatment of chronic hepatitis C genotype 1 infection in African-American patients: a community-based retrospective cohort study.
    Eur J Gastroenterol Hepatol. 2018 Aug 9. doi: 10.1097/MEG.0000000000001233.
    PubMed     Text format     Abstract available


  27. ALI N, Hussain W, Hayat A, Shah T, et al
    Prevalence and risk factors of hepatitis B and C viruses among haemodialysis patients: a multicentric study.
    Eur J Gastroenterol Hepatol. 2018 Aug 3. doi: 10.1097/MEG.0000000000001220.
    PubMed     Text format     Abstract available


    July 2018
  28. SONG BG, Sinn DH, Chi S, Kim K, et al
    Additional role of liver stiffness measurement in stratifying residual hepatocellular carcinoma risk predicted by serum biomarkers in chronic hepatitis B patients under antiviral therapy.
    Eur J Gastroenterol Hepatol. 2018 Jul 30. doi: 10.1097/MEG.0000000000001226.
    PubMed     Text format     Abstract available


  29. ELHELBAWY M, Abdel-Razek W, Alsebaey A, Hashim M, et al
    Insulin resistance does not impair response of chronic hepatitis C virus to direct-acting antivirals, and improves with the treatment.
    Eur J Gastroenterol Hepatol. 2018 Jul 18. doi: 10.1097/MEG.0000000000001215.
    PubMed     Text format     Abstract available


  30. ABDELAZIZ AO, Shousha HI, Said EM, A Soliman Z, et al
    Evaluation of liver steatosis, measured by controlled attenuation parameter, in patients with hepatitis C-induced advanced liver fibrosis and hepatocellular carcinoma.
    Eur J Gastroenterol Hepatol. 2018 Jul 17. doi: 10.1097/MEG.0000000000001196.
    PubMed     Text format     Abstract available


  31. SOLUND C, Andersen ES, Mossner B, Laursen AL, et al
    Outcome and adverse events in patients with chronic hepatitis C treated with direct-acting antivirals: a clinical randomized study.
    Eur J Gastroenterol Hepatol. 2018 Jul 9. doi: 10.1097/MEG.0000000000001192.
    PubMed     Text format     Abstract available


  32. HILL LA, Delmonte RJ, Andrews B, Richards L, et al
    Treatment of hepatitis C with direct-acting antivirals significantly reduces liver-related hospitalizations in patients with cirrhosis.
    Eur J Gastroenterol Hepatol. 2018 Jul 2. doi: 10.1097/MEG.0000000000001195.
    PubMed     Text format     Abstract available


  33. ALAVIAN SM, Sharafi H
    Comment on 'Efficacy of daclatasvir-based quadruple therapy in nonresponder patients infected by hepatitis C virus genotype 4: the ANRS HC32 QUATTRO study'.
    Eur J Gastroenterol Hepatol. 2018;30:807-808.
    PubMed     Text format    


  34. OZCELIK F, Sertoglu E
    Povital role of platelet count in platelet-lymphocyte count used in distinguishing patients with significant liver fibrosis and insulin resistance.
    Eur J Gastroenterol Hepatol. 2018;30:807.
    PubMed     Text format    


  35. COMBA A, Demirbas F, Caltepe G, Eren E, et al
    Retrospective analysis of children with alpha-1 antitrypsin deficiency.
    Eur J Gastroenterol Hepatol. 2018;30:774-778.
    PubMed     Text format     Abstract available


    June 2018
  36. VIEJO LG, Herola AG, Lloret IS, Ruano FS, et al
    Screening of hepatitis C virus infection in adult general population in Spain.
    Eur J Gastroenterol Hepatol. 2018 Jun 22. doi: 10.1097/MEG.0000000000001190.
    PubMed     Text format     Abstract available


  37. AGUILERA A, Rodriguez-Calvino J, de Mendoza C, Soriano V, et al
    Hepatitis delta in patients with resolved hepatitis B virus infection.
    Eur J Gastroenterol Hepatol. 2018 Jun 20. doi: 10.1097/MEG.0000000000001187.
    PubMed     Text format     Abstract available


  38. SHANMUGAM RP, Balakrishnan S, Varadhan H, Shanmugam V, et al
    Prevalence of hepatitis B and hepatitis C infection from a population-based study in Southern India.
    Eur J Gastroenterol Hepatol. 2018 Jun 8. doi: 10.1097/MEG.0000000000001180.
    PubMed     Text format     Abstract available


    May 2018
  39. YOON CH, Jin YJ, Lee JW
    Nonalcoholic fatty liver disease-associated hepatocellular carcinoma in a hepatitis B virus-endemic area.
    Eur J Gastroenterol Hepatol. 2018 May 29. doi: 10.1097/MEG.0000000000001174.
    PubMed     Text format     Abstract available


  40. ISAKOV V, Paduta D, Viani RM, Enejosa JV, et al
    Ombitasvir/paritaprevir/ritonavir+dasabuvir+ribavirin for chronic hepatitis C virus genotype 1b-infected cirrhotics (TURQUOISE-IV).
    Eur J Gastroenterol Hepatol. 2018 May 14. doi: 10.1097/MEG.0000000000001166.
    PubMed     Text format     Abstract available


  41. AGUILERA A, Trastoy R, Rodriguez-Calvino J, Manso T, et al
    Prevalence and incidence of hepatitis delta in patients with chronic hepatitis B in Spain.
    Eur J Gastroenterol Hepatol. 2018 May 8. doi: 10.1097/MEG.0000000000001163.
    PubMed     Text format     Abstract available


  42. CHEN B, Wang YH, Qian JQ, Wu DB, et al
    Human mesenchymal stem cells for hepatitis B virus-related acute-on-chronic liver failure: a systematic review with meta-analysis.
    Eur J Gastroenterol Hepatol. 2018 May 3. doi: 10.1097/MEG.0000000000001156.
    PubMed     Text format     Abstract available


  43. TACHI Y, Hirai T, Kojima Y, Ishizu Y, et al
    Predictive ability of shear wave elastography for pruritus in chronic hepatitis C patients with sustained virological response.
    Eur J Gastroenterol Hepatol. 2018 May 2. doi: 10.1097/MEG.0000000000001159.
    PubMed     Text format     Abstract available


  44. HUANG R, Wang J, Xia J, Hao Y, et al
    Platelets-to-lymphocyte ratio as a predictor of liver fibrosis and insulin resistance in hepatitis C virus infection: more evidence is needed.
    Eur J Gastroenterol Hepatol. 2018;30:583.
    PubMed     Text format    


  45. HASSANY M, Elsharkawy A, Maged A, Mehrez M, et al
    Hepatitis C virus treatment by direct-acting antivirals in successfully treated hepatocellular carcinoma and possible mutual impact.
    Eur J Gastroenterol Hepatol. 2018 May 1. doi: 10.1097/MEG.0000000000001152.
    PubMed     Text format     Abstract available


  46. FOUAD R, Elbaz T, Abdel Alem S, Elsharkawy A, et al
    Evaluation of accuracy of elastography point quantification versus other noninvasive modalities in staging of fibrosis in chronic hepatitis C virus patients.
    Eur J Gastroenterol Hepatol. 2018 May 1. doi: 10.1097/MEG.0000000000001151.
    PubMed     Text format     Abstract available


    April 2018
  47. MENDES LC, Ferreira PA, Miotto N, Zanaga L, et al
    Controlled attenuation parameter for steatosis grading in chronic hepatitis C compared with digital morphometric analysis of liver biopsy: impact of individual elastography measurement quality.
    Eur J Gastroenterol Hepatol. 2018 Apr 30. doi: 10.1097/MEG.0000000000001145.
    PubMed     Text format     Abstract available


  48. SPAHR L, Goossens N, Furrer F, Dupuis M, et al
    A return to harmful alcohol consumption impacts on portal hemodynamic changes following alcoholic hepatitis.
    Eur J Gastroenterol Hepatol. 2018 Apr 30. doi: 10.1097/MEG.0000000000001148.
    PubMed     Text format     Abstract available


  49. GOKCE O, Ozenirler S, Atak Yucel A, Oruklu N, et al
    Evaluation of serum procollagen C-proteinase enhancer 1 level as a fibrosis marker in patients with chronic hepatitis B.
    Eur J Gastroenterol Hepatol. 2018 Apr 20. doi: 10.1097/MEG.0000000000001123.
    PubMed     Text format     Abstract available


  50. JIN CN, Chen JD, Sheng JF
    Vitamin D deficiency in hepatitis C virus infection: what is old? what is new?
    Eur J Gastroenterol Hepatol. 2018 Apr 16. doi: 10.1097/MEG.0000000000001134.
    PubMed     Text format     Abstract available


  51. SPINICCI M, Emmi G, Dies L, Barilaro A, et al
    Safety of targeted prophylaxis strategy in patients with resolved hepatitis B virus infection receiving rituximab for immune-mediated diseases.
    Eur J Gastroenterol Hepatol. 2018 Apr 11. doi: 10.1097/MEG.0000000000001132.
    PubMed     Text format     Abstract available


  52. SU YC, Lin PC, Yu HC, Wu CC, et al
    Hepatitis B virus reactivation in patients with resolved hepatitis B virus infection receiving chemotherapy or immunosuppressive therapy.
    Eur J Gastroenterol Hepatol. 2018 Apr 4. doi: 10.1097/MEG.0000000000001130.
    PubMed     Text format     Abstract available


  53. EFE C, Ozaslan E, Purnak T
    Second-line immunosuppressants for autoimmune hepatitis.
    Eur J Gastroenterol Hepatol. 2018;30:490-491.
    PubMed     Text format    


  54. PONZETTO A, Figura N
    Helicobacter pylori infection among patients with liver cirrhosis.
    Eur J Gastroenterol Hepatol. 2018;30:490.
    PubMed     Text format    


  55. POYNARD T, Munteanu M, Charlotte F, Perazzo H, et al
    Impact of steatosis and inflammation definitions on the performance of NASH tests.
    Eur J Gastroenterol Hepatol. 2018;30:384-391.
    PubMed     Text format     Abstract available


    March 2018
  56. TONON M, Piano S, Romano A, Fasolato S, et al
    Assessment of bone mineral density in patients with cirrhosis treated with third-generation nucleos(t)ide analogues: comparison between tenofovir and entecavir.
    Eur J Gastroenterol Hepatol. 2018;30:284-290.
    PubMed     Text format     Abstract available


    February 2018
  57. KOBAYASHI N, Iijima H, Tada T, Kumada T, et al
    Changes in liver stiffness and steatosis among patients with hepatitis C virus infection who received direct-acting antiviral therapy and achieved sustained virological response.
    Eur J Gastroenterol Hepatol. 2018 Feb 28. doi: 10.1097/MEG.0000000000001106.
    PubMed     Text format     Abstract available


  58. PYRSOPOULOS N, Trilianos P, Lingiah VA, Fung P, et al
    The safety and efficacy of ledipasvir/sofosbuvir with or without ribavirin in the treatment of orthotopic liver transplant recipients with recurrent hepatitis C: real-world data.
    Eur J Gastroenterol Hepatol. 2018 Feb 23. doi: 10.1097/MEG.0000000000001101.
    PubMed     Text format     Abstract available


  59. SAGNELLI E, Stroffolini T, Sagnelli C, Cacopardo B, et al
    Characteristics of patients with hepatitis C virus-related chronic liver diseases just before the era of oral direct-acting antiviral therapy in Italy.
    Eur J Gastroenterol Hepatol. 2018 Feb 20. doi: 10.1097/MEG.0000000000001099.
    PubMed     Text format     Abstract available


  60. ZHANG Y, Shi Y, Wu R, Wang X, et al
    Primary biliary cholangitis is more severe in previous hepatitis B virus infection patients.
    Eur J Gastroenterol Hepatol. 2018 Feb 16. doi: 10.1097/MEG.0000000000001100.
    PubMed     Text format     Abstract available


  61. HUANG R, Zhao XA, Wang J, Hao Y, et al
    Simple noninvasive tests for the detection of advanced liver fibrosis in patients with chronic hepatitis B.
    Eur J Gastroenterol Hepatol. 2018;30:241.
    PubMed     Text format    


  62. ZHANG X, Qi X, Yoshida EM, Mendez-Sanchez N, et al
    Ischemic stroke in liver cirrhosis: epidemiology, risk factors, and in-hospital outcomes.
    Eur J Gastroenterol Hepatol. 2018;30:233-240.
    PubMed     Text format     Abstract available


    January 2018
  63. ADHOUTE X, Penaranda G, Raoul JL, Sellier F, et al
    Hepatocellular carcinoma recurrence in hepatitis C virus-related cirrhosis treated with direct-acting antivirals: a case-control study.
    Eur J Gastroenterol Hepatol. 2018 Jan 30. doi: 10.1097/MEG.0000000000001082.
    PubMed     Text format     Abstract available


  64. LULLAU A, Petroff D, Batz O, Kramer J, et al
    Linkage to care of HbsAg-positive and anti-HCV-positive patients after a systematic screening approach in the German primary care setting.
    Eur J Gastroenterol Hepatol. 2018 Jan 10. doi: 10.1097/MEG.0000000000001052.
    PubMed     Text format     Abstract available


  65. PANG Q, Zhou L, Qu K, Cui RX, et al
    Validation of inflammation-based prognostic models in patients with hepatitis B-associated hepatocellular carcinoma: a retrospective observational study.
    Eur J Gastroenterol Hepatol. 2018;30:60-70.
    PubMed     Text format     Abstract available


    December 2017
  66. ROULOT D, Thibault V, Laforest C, Fontaine H, et al
    Efficacy of daclatasvir-based quadruple therapy in nonresponder patients infected by hepatitis C virus genotype 4: the ANRS HC32 QUATTRO study.
    Eur J Gastroenterol Hepatol. 2017 Dec 21. doi: 10.1097/MEG.0000000000001035.
    PubMed     Text format     Abstract available


  67. ALSEBAEY A, Elhelbawy M, Waked I
    Platelets-to-lymphocyte ratio is a good predictor of liver fibrosis and insulin resistance in hepatitis C virus-related liver disease.
    Eur J Gastroenterol Hepatol. 2017 Dec 13. doi: 10.1097/MEG.0000000000001013.
    PubMed     Text format     Abstract available


  68. DE LEMOS-BONOTTO M, Valle-Tovo C, Costabeber AM, Mattos AA, et al
    A systematic review and meta-analysis of second-line immunosuppressants for autoimmune hepatitis treatment.
    Eur J Gastroenterol Hepatol. 2017 Dec 8. doi: 10.1097/MEG.0000000000001019.
    PubMed     Text format     Abstract available


  69. BASHIR MH, Fazili J, Madhoun MF, Kanagala R, et al
    Impact of sustained virologic response on short-term clinical outcomes in hepatitis C-related cirrhosis.
    Eur J Gastroenterol Hepatol. 2017 Dec 1. doi: 10.1097/MEG.0000000000001032.
    PubMed     Text format     Abstract available


    November 2017
  70. LIN Z, Liang J, Zhu J, Hu C, et al
    Diverse correlations between fibrosis-related factors and liver stiffness measurement by transient elastography in chronic hepatitis B.
    Eur J Gastroenterol Hepatol. 2017 Nov 29. doi: 10.1097/MEG.0000000000001023.
    PubMed     Text format     Abstract available


  71. MOSER S, Kozbial K, Laferl H, Schutz A, et al
    Efficacy of ledipasvir/sofosbuvir plus ribavirin for 12 weeks in patients with chronic hepatitis C genotype 3 and compensated liver disease.
    Eur J Gastroenterol Hepatol. 2017 Nov 8. doi: 10.1097/MEG.0000000000001027.
    PubMed     Text format     Abstract available


  72. SAAD Y, Awad A, Alakel W, Doss W, et al
    Data mining of routine laboratory tests can predict liver disease progression in Egyptian diabetic patients with hepatitis C virus (G4) infection: a cohort study of 71 806 patients.
    Eur J Gastroenterol Hepatol. 2017 Nov 2. doi: 10.1097/MEG.0000000000001008.
    PubMed     Text format     Abstract available


  73. HUANG R, Wang J, Zhao XA, Xia J, et al
    The impact of cirrhosis on the efficacy and safety of entecavir for patients with chronic hepatitis B.
    Eur J Gastroenterol Hepatol. 2017;29:1314.
    PubMed     Text format    


    October 2017
  74. ABDELAZIZ AO, Nabil MM, Abdelmaksoud AH, Shousha HI, et al
    De-novo versus recurrent hepatocellular carcinoma following direct-acting antiviral therapy for hepatitis C virus.
    Eur J Gastroenterol Hepatol. 2017 Oct 23. doi: 10.1097/MEG.0000000000001004.
    PubMed     Text format     Abstract available


  75. SIMONETTI G, Gitto S, Golfieri L, Gamal N, et al
    Quality of life of hepatitis B virus surface antigen-positive patients with suppressed viral replication: comparison between inactive carriers and nucleot(s)ide analog-treated patients.
    Eur J Gastroenterol Hepatol. 2017 Oct 23. doi: 10.1097/MEG.0000000000000999.
    PubMed     Text format     Abstract available


  76. WIJARNPREECHA K, Chesdachai S, Jaruvongvanich V, Ungprasert P, et al
    Hepatitis C virus infection and risk of Parkinson's disease: a systematic review and meta-analysis.
    Eur J Gastroenterol Hepatol. 2017 Oct 18. doi: 10.1097/MEG.0000000000000991.
    PubMed     Text format     Abstract available


  77. KORDA D, Lenard ZM, Gerlei Z, Jakab Z, et al
    Shear-wave elastography for the assessment of liver fibrosis in liver transplant recipients treated for hepatitis C virus recurrence.
    Eur J Gastroenterol Hepatol. 2017 Oct 18. doi: 10.1097/MEG.0000000000001003.
    PubMed     Text format     Abstract available


  78. ABDEL-RAZIK A, Mousa N, Zakaria S, Elhelaly R, et al
    New predictive factors of poor response to therapy in autoimmune hepatitis: role of mean platelet volume.
    Eur J Gastroenterol Hepatol. 2017 Oct 13. doi: 10.1097/MEG.0000000000000982.
    PubMed     Text format     Abstract available


  79. FAN Y, Cao W, Di H, Liu C, et al
    Assessment of liver fibrosis with acoustic radiation force impulse in patients with chronic hepatitis C.
    Eur J Gastroenterol Hepatol. 2017;29:1190.
    PubMed     Text format    


    September 2017
  80. MOHAMED MS, Hanafy AS, Bassiony MAA, Hussein S, et al
    Sofosbuvir and daclatasvir plus ribavirin treatment improve liver function parameters and clinical outcomes in Egyptian chronic hepatitis C patients.
    Eur J Gastroenterol Hepatol. 2017 Sep 25. doi: 10.1097/MEG.0000000000000963.
    PubMed     Text format     Abstract available


  81. TRIANTOS CK, Tsintoni A, Karaivazoglou K, Grigoropoulou X, et al
    Male hepatitis C patients' sexual functioning and its determinants.
    Eur J Gastroenterol Hepatol. 2017 Sep 13. doi: 10.1097/MEG.0000000000000971.
    PubMed     Text format     Abstract available


  82. WRIGHT N, Reimer J, Somaini L, Roncero C, et al
    Are we ready to treat hepatitis C virus in individuals with opioid use disorder: assessment of readiness in European countries on the basis of an expert-generated model.
    Eur J Gastroenterol Hepatol. 2017 Sep 13. doi: 10.1097/MEG.0000000000000962.
    PubMed     Text format     Abstract available


  83. LANG S, Kutting F, Staub A, Schramowski J, et al
    Performance of simple noninvasive scoring systems for the prediction of advanced fibrosis in patients with chronic hepatitis B.
    Eur J Gastroenterol Hepatol. 2017 Sep 6. doi: 10.1097/MEG.0000000000000977.
    PubMed     Text format     Abstract available


  84. MILAZZO L, Magni C, Niero F, Schiavini M, et al
    Retreatment of chronic hepatitis C virus infection after unsuccessful therapy with all-oral direct-acting antiviral regimens: a real-life experience.
    Eur J Gastroenterol Hepatol. 2017 Sep 4. doi: 10.1097/MEG.0000000000000965.
    PubMed     Text format     Abstract available


  85. MOUSA N, Abdel-Razik A, Farag R, Shabana W, et al
    Do we need to screen for de-novo diabetes mellitus in chronic hepatitis C patients after a sustained virological response?
    Eur J Gastroenterol Hepatol. 2017;29:1004-1009.
    PubMed     Text format     Abstract available


  86. TRIANTOS C, Kalafateli M, Aggeletopoulou I, Mandellou M, et al
    Lactate serum concentrations during treatment with nucleos(t)ide analogues in hepatitis B with or without cirrhosis.
    Eur J Gastroenterol Hepatol. 2017;29:998-1003.
    PubMed     Text format     Abstract available


    August 2017
  87. DOLMAZASHVILI E, Abutidze A, Chkhartishvili N, Karchava M, et al
    Regression of liver fibrosis over a 24-week period after completing direct-acting antiviral therapy in patients with chronic hepatitis C receiving care within the national hepatitis C elimination program in Georgia: results of hepatology clinic HEPA e
    Eur J Gastroenterol Hepatol. 2017 Aug 29. doi: 10.1097/MEG.0000000000000964.
    PubMed     Text format     Abstract available


  88. SIMS OT, Guo Y, Shoreibah MG, Venkata K, et al
    Alcohol and substance use, race, and insurance status predict nontreatment for hepatitis C virus in the era of direct acting antivirals: a retrospective study in a large urban tertiary center.
    Eur J Gastroenterol Hepatol. 2017 Aug 29. doi: 10.1097/MEG.0000000000000961.
    PubMed     Text format     Abstract available


  89. MANGLA N, Mamun R, Weisberg IS
    Viral hepatitis screening in transgender patients undergoing gender identity hormonal therapy.
    Eur J Gastroenterol Hepatol. 2017 Aug 29. doi: 10.1097/MEG.0000000000000950.
    PubMed     Text format     Abstract available


  90. KARAIVAZOGLOU K, Tsermpini EE, Assimakopoulos K, Triantos C, et al
    Sexual functioning in patients with chronic hepatitis C: a systematic review.
    Eur J Gastroenterol Hepatol. 2017 Aug 22. doi: 10.1097/MEG.0000000000000949.
    PubMed     Text format     Abstract available


  91. MIOTTO N, Mendes LC, Zanaga LP, Goncales ESL, et al
    Predictors of early discontinuation of interferon-free direct antiviral agents in patients with hepatitis C virus and advanced liver fibrosis: results of a real-life cohort.
    Eur J Gastroenterol Hepatol. 2017 Aug 10. doi: 10.1097/MEG.0000000000000944.
    PubMed     Text format     Abstract available


    July 2017
  92. POGORZELSKA J, Lapinska M, Kalinowska A, Lapinski TW, et al
    Helicobacter pylori infection among patients with liver cirrhosis.
    Eur J Gastroenterol Hepatol. 2017 Jul 11. doi: 10.1097/MEG.0000000000000928.
    PubMed     Text format     Abstract available


    June 2017
  93. FERNANDES SR, Marques da Costa P, Vitor S, Carvalho JR, et al
    Predicting short-term and long-term mortality of hospitalized Portuguese patients with alcoholic hepatitis.
    Eur J Gastroenterol Hepatol. 2017 Jun 16. doi: 10.1097/MEG.0000000000000926.
    PubMed     Text format     Abstract available


  94. VEIGA ZST, Villela-Nogueira CA, Fernandes FF, Cavalcanti MG, et al
    Transient elastography evaluation of hepatic and spleen stiffness in patients with hepatosplenic schistosomiasis.
    Eur J Gastroenterol Hepatol. 2017;29:730-735.
    PubMed     Text format     Abstract available


    May 2017
  95. SERIGADO JM, Izzy M, Kalia H
    Novel therapies and potential therapeutic targets in the management of chronic hepatitis B.
    Eur J Gastroenterol Hepatol. 2017 May 19. doi: 10.1097/MEG.0000000000000911.
    PubMed     Text format     Abstract available


  96. STROFFOLINI T, Sagnelli E, Almasio PL, Andriulli A, et al
    Etiological factors of chronic hepatitis in Italy: a 2014 national survey.
    Eur J Gastroenterol Hepatol. 2017 May 19. doi: 10.1097/MEG.0000000000000907.
    PubMed     Text format     Abstract available


  97. WANG PC, Wei TY, Tseng TC, Lin HH, et al
    Cirrhosis has no impact on therapeutic responses of entecavir for chronic hepatitis B.
    Eur J Gastroenterol Hepatol. 2017 May 19. doi: 10.1097/MEG.0000000000000897.
    PubMed     Text format     Abstract available


  98. JABLONKA A, Solbach P, Wobse M, Manns MP, et al
    Seroprevalence of antibodies and antigens against hepatitis A-E viruses in refugees and asylum seekers in Germany in 2015.
    Eur J Gastroenterol Hepatol. 2017 May 10. doi: 10.1097/MEG.0000000000000889.
    PubMed     Text format     Abstract available


  99. HUANG R, Xia J, Liu Y, Zhang Z, et al
    Acoustic radiation force impulse in the diagnosis of liver fibrosis in patients with chronic hepatitis B.
    Eur J Gastroenterol Hepatol. 2017 May 3. doi: 10.1097/MEG.0000000000000902.
    PubMed     Text format    


  100. WAHID B, Saleem K, Ali A, Rafique S, et al
    Rising relapse rate in hepatitis C virus type 3a-infected patients against sofosbuvir and ribavirin combination therapy: a Pakistani experience.
    Eur J Gastroenterol Hepatol. 2017 May 3. doi: 10.1097/MEG.0000000000000895.
    PubMed     Text format    


  101. KOHLA MAS, Abbasy M, Abozeid M, El-Abd O, et al
    Assessment of liver fibrosis with acoustic radiation force impulse imaging versus liver histology in patients with chronic hepatitis C: a pilot study.
    Eur J Gastroenterol Hepatol. 2017 May 3. doi: 10.1097/MEG.0000000000000903.
    PubMed     Text format     Abstract available


  102. CHEN D, Luo S, Ben Q, Lu L, et al
    Prevalence of hepatitis B and C and factors for infection and nonimmune in inflammatory bowel disease patients in China.
    Eur J Gastroenterol Hepatol. 2017;29:509-515.
    PubMed     Text format     Abstract available


  103. IINO C, Shimoyama T, Igarashi T, Aihara T, et al
    Usefulness of the Glasgow-Blatchford score to predict 1-week mortality in patients with esophageal variceal bleeding.
    Eur J Gastroenterol Hepatol. 2017;29:547-551.
    PubMed     Text format     Abstract available


  104. SOURIANARAYANANE A, Talluri J, Humar A, McCullough AJ, et al
    Stage of fibrosis and portal pressure correlation in nonalcoholic steatohepatitis.
    Eur J Gastroenterol Hepatol. 2017;29:516-523.
    PubMed     Text format     Abstract available


    April 2017
  105. CORDERO-RUIZ P, Carmona-Soria I, Rodriguez-Tellez M, Caunedo-Alvarez A, et al
    Long-term follow-up of patients with chronic hepatitis C treated with alpha-interferon and ribavirin antiviral therapy: clinical and fibrosis impact of treatment response.
    Eur J Gastroenterol Hepatol. 2017 Apr 25. doi: 10.1097/MEG.0000000000000886.
    PubMed     Text format     Abstract available


  106. MARCELLIN F, Protopopescu C, Esterle L, Wittkop L, et al
    Anger and quality of life in patients co-infected with HIV and hepatitis C virus: a cross-sectional study (ANRS CO13-HEPAVIH).
    Eur J Gastroenterol Hepatol. 2017 Apr 17. doi: 10.1097/MEG.0000000000000883.
    PubMed     Text format     Abstract available


  107. TABERNILLA A, Grandal M, Pernas B, Castro-Iglesias A, et al
    Viral dynamics among hepatitis C virus chronic infected patients during direct-acting antiviral agents therapy: impact for monitoring and optimizing treatment duration.
    Eur J Gastroenterol Hepatol. 2017 Apr 13. doi: 10.1097/MEG.0000000000000882.
    PubMed     Text format     Abstract available


    March 2017
  108. SHERIGAR JM, Gayam V, Khan A, Mukhtar O, et al
    Clinical efficacy and tolerability of direct-acting antivirals in elderly patients with chronic hepatitis C.
    Eur J Gastroenterol Hepatol. 2017 Mar 24. doi: 10.1097/MEG.0000000000000871.
    PubMed     Text format     Abstract available


  109. JI F, Tian C, Li Z, Deng H, et al
    Ledipasvir and sofosbuvir combination for hepatitis C virus infection in three patients aged 85 years and older.
    Eur J Gastroenterol Hepatol. 2017 Mar 21. doi: 10.1097/MEG.0000000000000873.
    PubMed     Text format    


  110. MURATORI P, Efe C, Muratori L, Ozaslan E, et al
    Clinical implications of antimitochondrial antibody seropositivity in autoimmune hepatitis: a multicentre study.
    Eur J Gastroenterol Hepatol. 2017 Mar 21. doi: 10.1097/MEG.0000000000000870.
    PubMed     Text format     Abstract available


  111. TANWAR S, Trembling PM, Hogan BJ, Srivastava A, et al
    Noninvasive markers of liver fibrosis: on-treatment changes of serum markers predict the outcome of antifibrotic therapy.
    Eur J Gastroenterol Hepatol. 2017;29:289-296.
    PubMed     Text format     Abstract available


    February 2017
  112. LIONCO LC, de Mattos AA, Horbe AF, Costabeber AM, et al
    Treatment of hepatocellular carcinoma using transarterial chemoembolization: a real-life, single-centre study from Southern Brazil.
    Eur J Gastroenterol Hepatol. 2017;29:225-230.
    PubMed     Text format     Abstract available


    January 2017
  113. ZHU S, Waili Y, Qi X, Chen Y, et al
    Lymphocyte-monocyte ratio at admission predicts possible outcomes in patients with acute-on-chronic liver failure.
    Eur J Gastroenterol Hepatol. 2017;29:31-35.
    PubMed     Text format     Abstract available


  114. PAPADOPOULOS N, Deutsch M, Manolakopoulos S, Bitsi C, et al
    Efficacy of prophylactic antiviral therapy and outcomes in HBsAg-negative, anti-HBc-positive patients receiving chemotherapy: a real-life experience.
    Eur J Gastroenterol Hepatol. 2017;29:56-60.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Hepatitis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: